Healthcare
Monday, August 22, 2016
BRIEF-Lilly and Astrazeneca receive FDA fast track designation for AZD3293
* Lilly and Astrazeneca receive FDA fast track designation
for AZD3293, an investigational treatment for early Alzheimer's
disease
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment